Salem Cancer Institute - A part of Salem Health

Eligibility
Temporarily closed to patient enrollment while data is analyzed.
Histological proof of Glioblastoma. Prior treatment with Temozolomide/RT required. No other chemo is allowed. Previous participation in RTOG 0525 is allowed. Age >/=18. Performance Status >/= 60%.

Eligibility
Histologically confirmed adenocarcinoma of the breast at significant risk of distant recurrence based on at least one of the following: Involvement of 1 lymph node on routine histologic exam; ER negative >/= 1 cm; ER+ tumor >/+ 5 cms regardless of recurrence score; ER+ tumor >/= 1 cm < 5 cm with recurrence score of >/= 11(may also be enrolled in the TailorX Trial); Completed definitive breast surgery; Margins histologically free of IBC or DCIS(LCIS allowed); Must start tx between day 28 and 84 from surgery;Must have RT if undergone BCS or undergone mastectomy with tumor > 5 cm or 4+ LNs; No HER2+; No inflammatory or fixed LNs at diagnosis; No Prior Chemo/Hormonal therapy for this breast cancer; No prior anthracycline, anthracenedione or taxane; Prior use of tamoxifen(prevention) and raloxifine must be discontinued at study entry

Eligibility
ER Positive and/or PR Positive. Axillary Node Negative. Candidate for adjuvant cytotoxic therapy in addition to hormonal therapy.

Eligibility
Stage 0, 1, or 2 breast cancer. If stage 2, tumor size must be <3cm. Clear margins. No more than 3 histological positive axillary nodes. Women who are >50 with DCIS only, or over 50 with invasive, node neg and hormone positive are not eligible.

Eligibility
Postmenopausal. Pathologic or clinical stage I, II, IIIA. ER and/or PgR positive. Hormonal therapy must have consisted of an AI or a combo of up to 3 years Tamoxifen followed by an AI. Tamoxifen may not have been given during years 4 & 5 of adjuvant hormonal therapy.

Eligibility
Incurable locally advanced or metastatic breast cancer with measurable or evaluable disease. Subjects with bone only mets that can be imaged with bone scan and MRI or bone scan and plain x-ray are eligible. Must be hormone receptor positive defined as >=10%. Must be Her2neg. Patients must have received a third generation aromatase inhibitor and progressed through prior palliative therapy, recurred while on an adjuvant aromatase inhibitor, or recurred within 12 months of completing an adjuvant aromatase inhibitor. Concurrent use of bisphophonates will be permitted on this study. Male or female subjects are ok. Female subjects must be post-menopausal. Lab values must be WNL.

Eligibility
Women or men with Stage IV breast cancer which is bone-predominant.

Eligibility
Operable stage I, II, or IIIA invasive breast cancer. Tumors must be ER & PR negative. Must be premenopausal. Must have modified radical mastectomy or local excision plus axillary lymph node dissection and/or sentinel node. Planned treatment must include 3-8 cycles of chemotherapy.

Eligibility
Patients with primary, untreated histologically confirmed invasive squamous, adeno, or adenosquamous of the cervix. Stages IB2, IIA, IIB, and IVA. Must have negative, non-suspicious para-aortic nodes. Stage IIIA (lower one-third vaginal involvement) are not eligible.

Eligibility
Diagnosed with any phase ph+ or bcr-abl confirmed CML within 6 months of entry into the Registry. Provided informed consent.

Eligibility
Histologically confirmed adenocarcinoma of the colon that is Stage II (T3,4 NO,MO). Distal extent of tumor must be >/= 12 cm from the anal verge as determined via endoscopy or surgery. Patients must have >/= 8 lymph nodes evaluable and reported. Patients must have paraffin-embedded tumor specimen available for central evaluation and risk assessment. No isolated, distant, or intra-abdominal mets. Patients must not have presented with complete obstruction or perforation of the bowel. No prior radiation therapy for this malignancy. Must have post-operative evidence of adequate hepatic and renal function.

Eligibility
Histologically documented adenocarcinoma of the colon that has been completely resected. At least 1 pathologically confirmed positive lymph node identified. No evidence of residual lymph node disease. Randomization must occur <56 days post surgery. Patients with > one synchronous primary colon cancer are eligible. Performance Status 0-2. No distant metastatic disease and no prior chemo or radiation therapy. Patients with certain cardiac conditions are ineligible.

Eligibility
Pending IRB Review Dec 2008
Age 18-80. Biopsy proven unresectable metastatic adeno of the color or rectum. Documented progression on prior first-line oxaliplatin-based or irinotecan-based regimen for metastatic colorectal cancer. Measurable disease of at least >1cm. First-line treatmetn must have been completed at least 4 weeks prior to study trx. Use of biologic agents with first-line chemotherapy permitted. Previous adjuvant regimens must have been greater than 6 months before inclusion. Adequate oregon function. No prior trx with erlotinib or gefitinib. No CNS mets. No untreated or unresolved bowel obstruction. No angina or uncontrolled CHF.

Eligibility
Histologically proven diagnosis, via endoscopy, of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction within 6 weeks of registration. All disease must be encompassed in the radiotherapy field. Stage T1N1MO; T2-4,Any N, MO; Any T, Any N, M1a. Patient's total caloric intake must be at least 1500 calories a day. No evidence of tracheoesophageal fistula or invasion into the major bronchi. No prior chemotherapy for esophageal cancer.

Eligibility
Histologically diagnosed adenocarcinoma of stomach or gastroesophageal junction.Patients must have had en bloc resection of all known tumor with curative intent.Patients must have tumor extension beyond muscularis propria and/or nodal involvement. No known unresected tumor, recurent cancer, microscopic evidence of tumor at the distal or proximal line of stomach rescetion, or noncontiguous resection allowed. No M1 disease. No previous chemo, or RT. Patient must have stable weight for at least one week prior to registration. Must be evaluated by a radiation oncologist.

Eligibility
Biopsy proven GIST that is distantly metastatic or unresectable. Measurable and/or non-measurable disease. May have received traditional chemo agents. At least 28 days since completion. No prior imatinib, bevacizumab, or other agents targeting KIT, VEGF, VEGFR, or PDGFR for advanced disease. Those agents may have been used in the adjuvant setting if patient did not recur for at least 12 months following therapy. Prior RT allowed if 28 days post.

Eligibility
Histologically or cytologically confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin. Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy. Written informed consent. Registry participation does not exclude participation in clinical trials. Patients scheduled to receive, or who have received surgery, are eligible for registry participation as long as they are also scheduled to receive medical therapy.

Eligibility
Histologic or cytologic stage IIIB or IV NSCLC. No brain mets or spinal cord compression. Patients must have received 4 cycles of platinum-based doublet therapy with or without bevacizumab. No evidence of disease progression. No prior adjuvant chemo for stage I-III resected or combined modality therapy for stage III NSCLC. Cardiac restrictions apply.

Eligibility
Complete resection of Stage 1B (>4cm)- IIIA non-small cell lung cancer. Wedge resection or segmentectomy will not be accepted. Lymph node sampling is expected. Refer to protocol for specifics. Patients must be no less than 6 weeks and no more than 12 weeks post-thoracotomy at the time of randomization and must be adequately recovered fom surgery. Performance status 0 or 1. No prior chemo allowed. Hormonal therapy or radiation therapy as prior cancer treatment within 5 years of randomization for a malignancy over 5 years that is now considered cured is acceptable. No myocardial infarction within 12 months. Patients with any history of cerebral vascular accident (CVA) or transient ischemic attack (TIA)will not be allowed on trial. Patients with on-going post-operative hemoptysis are not eligible. Pre-operative hemoptysis that has resolved post-operatively are eligible.

Eligibility
Biopsy proven incompletely resected or unresectable BAC or BAC variants. Stage IIIB or IV. Measurable or non-measurable disease. Must be willing to provide smoking history. Adequate lab functions. Prior surgery or RT completed 28 days prior. If pallative RT then 14 days must have elapsed and recovered from toxicities. No squamous component. No history of 1/2 tsp hemoptysis within 28 days of registration. No history of stroke, thromboses, or hemmorrhage.

Eligibility
Must be registered to a treatment protocol: S0536; S0424

Eligibility
Must be registered to a treatment protocol.

Eligibility
Must be registered to a treatment protocol: 8410; 8503; 8508; 8516; 8736; 8809; 8907; 8954; 9125; 9240; 9320; 9349; 9432; 9501; 9703; S9704; 9800

Eligibility
Biopsy proven malignant melanoma of cutaneous or mucosal orgin. Patients with ocular melanoma are not eligible. Patients must have unresectable disease. Patients must have Stage IV disease. Must have measurable disease. Must have negative CT/MRI of brain within 42 days of registration. No prior systemic therapy for Stage IV disease. Prior adjuvant therapy is allowed and may include cytoxic agents, but the interval from most recent exposure until registration must be at least 90 days. Prior RT is allowed if completed at least 28 days prior to registration. Adequate labs.

Eligibility
Melanoma of a cutaneous orgin. Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a,. Patients must complete all primary therapy (wide exicision with or without lymphadenectomy) and be randomized within 84 days of their wide excision. No prior chemotherapy, radiotherapy, or immunotherapy for melanoma allowed.

Eligibility
Previously Untreated Metastatic Hormone Refractory Prostate Cancer

Eligibility
Histologically confirmed prostate cancer within 180 days prior to registration. Pretreatment serum PSA obtained prior to any LHRH or antiandrogen therapy. Prior 5-alpha reductase inhibitor (finasteride) for prostatic hypertrophy is allowed if discontinued at least 60 days prior to registration. Prior testosterone administration is allowed if last administered at least 90 days prior to registration. Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation is < = 50 days prior to the date of registration. INELIGIBILTY: PSA > 150. Evidence of M1 disease. Positive lymph nodes or nodes > 1.5 cm on imaging. Prior radical prostatectomy, cryosurgery, bilateral orchiectomy, malignancy, systemic chemotherapy, radiotherapy including brachytherapy within current treatment field. Severe, active co-morbidity such as unstable angina or CHF requiring hospitalization with the last 6 months. Prior MI with the last 6 months. Existing neuropathy > grade 2.

Eligibility
Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy (NO) or lymph node status pathologically unknown (undissected pelvic lymph nodes); Post radical prostatectomy entry PSA => 0.2 and =<2.0 ng/ml at least 6 weeks after prostatectomy and within 30 days of registration; Must be T3N0/NX, T2NO/NX with positive prostatectomy margin and/or positive prostatic fossa; or urethral-vesical anastomosis biopsies; Gleason score of 8 or less; PSA doubling time of > 6 months; No distant mets allowed; Adequate lab values; No N1 disease.

Eligibility
Patients with histological or cytological confirmed RCC T1B, T2, T3 and T4 with any N. Patients must have undergone full surgical resection - radical or partial nephrectomy by either open or laparoscopic technique, with clear margins. Positive regional LNs require regional lymphadenectomy. Patients must not have CT or MRI evidence of residual or metastatic disease. Must have tumor specimen available for specimen submission. Must not have collecting duct or medullary carcinoma. No prior anticancer treatments for RCC either in the adjuvant or neoadjuvant setting. Patients must be 3-10 weeks post surgery at randomization in order to begin protocol treatment 4-12 weeks from surgery.

Eligibility
Histologic diagnosis of RCC with a component of clear cell or papillary carcinoma. RCC histology without any component of clear cell or papilary is not eligible. Patients must have radiographic or clinical evidence of mets or unresectable disease. Prior nephrectomy is not required. At least one measurable site of disease by RECIST criteria. P. Status 0,1,2. Adequate organ function.